Back to List/Filter


TRANSFORM-1

NCT04472598

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1)
Alfred Health (Haematology)
The Alfred, Commercial Road, Melbourne VIC, Australia
Closed
Primary Contact : John Nguyen, john.nguyen@alfred.org.au , 03 9076 7135
Gosford Hospital (Haematology)
Holden St, Gosford NSW 2250, Australia
Closed
Primary Contact : Mark Lacey, Mark.Lacey@health.nsw.gov.au , 02 4320 3940
Liverpool Hospital (Haematology)
1 Campbell St, Liverpool NSW 2170, Australia
Closed
Primary Contact : Pinky Patel, pinky.patel@health.nsw.gov.au , 0474 279 274
Secondary Contact : Sharon Young, Sharon.young@health.nsw.gov.au
Peter MacCallum - Parkville Cancer Clinical Trials Unit (PCCTU) (Haematology)
Peter MacCallum Cancer Centre, Grattan Street, Melbourne VIC, Australia
Closed
Primary Contact : Enquiry Line Coordinator, clinicaltrials.enquiries@petermac.org , +613 8559 7456
St Vincents Hospital Sydney (Haematology)
St Vincent's Hospital Sydney, Victoria Street, Darlinghurst NSW, Australia
Closed
Primary Contact : Georgia McCaughan, georgia.mccaughan@svha.org.au , 02 9355 5656

2020-000097-15M16-191

Interventional

Treatment - Drugs

Phase 3

18

100

09/11/2020

N/A

Closed

By Specialist and/or Surgeon Referral

Any or not stated

No

No

No
Haematology
Myeloproliferative Disorders
Myelofibrosis
N/A

20110048